Key result
Sarcopenia linked to ~119% greater 5-month readmission risk.
Why the study?
The prevalence of sarcopenia, its associated factors, and its impact on readmission were unknown in older hospitalized patients with cardiovascular disease in Vietnam.
Does sarcopenia increase the risk of readmission in older hospitalized patients with cardiovascular disease?
Cohort (n=251)
No
Does sarcopenia increase the risk of readmission in older hospitalized patients with cardiovascular disease?
Odds Ratio: 2.19 (95% CI 1.08–4.42)
Absolute Event Rate: 50% vs 27.9%
p-value: p=.001
Sarcopenia is highly prevalent in older hospitalized patients with cardiovascular disease and independently doubles the risk of 5-month readmission.
Sarcopenia may flag readmission risk in older adults; hypothesis-generating and should not yet change practice.
OBJECTIVE: To investigate the prevalence of sarcopenia, its associated factors and its impact on readmission in older hospitalised patients with cardiovascular diseases (CVD) in Vietnam. METHODS: Patients aged ≥60 with CVD were recruited from 12/2018 to 6/2019 at a tertiary hospital in Vietnam. Sarcopenia was defined by the criteria proposed by the Asian Working Group for Sarcopenia (AWGS). RESULTS: There were 251 participants, with a mean age of 73.7 ± 8.8, 39.4% were female, and 34.3% had sarcopenia. On multivariable logistic regression, heart failure, chronic kidney disease and being currently unmarried were significantly associated with sarcopenia. The incidence of 5-month readmission was 35.7% (50.0% in sarcopenic participants and 27.9% in non-sarcopenic participants, P = .001). Sarcopenia independently increased the risk of readmission (adjusted OR 2.19, 95% CI 1.08-4.42). CONCLUSION: Sarcopenia was present in one-third of older hospitalised patients with CVD and increased their risk of readmission. This finding suggests the need to raise awareness of sarcopenia among clinicians and older patients in Vietnam.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2020) conducted a cohort in Cardiovascular diseases (n=251). Sarcopenia vs. Non-sarcopenic participants was evaluated on 5-month readmission (adjusted OR 2.19, 95% CI 1.08-4.42, p=.001). Sarcopenia independently increased the risk of 5-month readmission compared to non-sarcopenic patients (50.0% vs 27.9%; adjusted OR 2.19; 95% CI 1.08-4.42).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: